Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.75 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.75 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.75 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.75 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Noribogaine SCHEMBL4400755 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL31738806 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL29929979 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL29363147 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL17145169 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL12938454 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL15070074 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL10036152 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL10059710 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Noribogaine SCHEMBL13258554 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 980 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616706-B2 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | Arbormentis LLC (US) | 2026-05-05 | — | — | US | claimed |
| WO-2025123137-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | 10763942 CANADA INC. (DBA. PURMINDS NEUROPHARMA) (CA) | 2025-06-19 | — | — | WO | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| US-20240398751-A1 | Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| WO-2024220576-A2 | PRODUCTION OF MONOTERPENE INDOLE ALKALOID COMPOUNDS IN A HETEROLOGOUS HOST | ATAI Life Sciences AG (DE) | 2024-10-24 | — | — | WO | claimed |
| US-20240325407-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | ATAI THERAPEUTICS, INC. | 2024-10-03 | — | — | US | claimed |
| US-20240325342-A1 | Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| US-20240299341-A1 | Methods of treating or reducing symptoms of nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation via combination therapy with allosteric modulators and phenethylamines. | HELDRETH JR DAVID ALAN (US) | 2024-09-12 | — | — | US | claimed |
| EP-1326997-A2 | MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION | The Regents of the University of California (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020061515-A1 | Model for neurodegenerative diseases involving amyloid accumulation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-23 | — | — | US | claimed |
| WO-2002026107-A2 | MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-04-04 | — | — | WO | claimed |
| US-6348456-B1 | TREATMENT FOR ADDICTION USING NORIBOGAINE AND 12-HYDROXY IBOGAMINE | DEMERX, INC. | 2002-02-19 | — | — | US | claimed |
| EP-1009407-A2 | NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION | Novoneuron, Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0804200-A4 | A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR | NDA INT INC (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1999011250-A2 | NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION | NOVONEURON, INC. (US) | 1999-03-11 | — | — | WO | claimed |
| EP-0804200-A1 | A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR | NDA INTERNATIONAL, INC. (US) | 1997-11-05 | — | — | EP | claimed |
| US-5591738-A | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | NDA INTERNATIONAL, INC. (US) | 1997-01-07 | — | — | US | claimed |
| WO-1996003127-A1 | A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR | NDA INTERNATIONAL, INC. (US) | 1996-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616706-B2 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | HTR2C, HTR2A, PNMT | SLC6A4 47/4885OPRM1 31/4885OPRK1 46/4885 |
| US-20250017846-A1 | TOPICAL ANALGESICS | OPRK1, OPRL1, OPRM1 | SLC6A4 613/4885OPRM1 3/4885OPRK1 1/4885 |
| US-20240325407-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | OPRK1, OPRM1, OPRD1 | SLC6A4 887/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | SLC6A4 326/4885OPRM1 50/4885OPRK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.